MaxCyte, Inc. Net Fee Amt
MaxCyte, Inc. (MXCT) had Net Fee Amt of $110.48 as of 2026-04-14, per its S-8 filed 2026-04-15.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-15
- 2026-04-14: Net Fee Amt $110.48.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-14 | $110.48 S-8 · filed 2026-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |